Robeco Institutional Asset Management B.V. Purchases New Stake in Cellebrite DI Ltd. (NASDAQ:CLBT)

Robeco Institutional Asset Management B.V. bought a new stake in Cellebrite DI Ltd. (NASDAQ:CLBT - Free Report) in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 197,554 shares of the company's stock, valued at approximately $3,838,000. Robeco Institutional Asset Management B.V. owned 0.08% of Cellebrite DI as of its most recent SEC filing.

Several other institutional investors and hedge funds have also added to or reduced their stakes in CLBT. Gen Wealth Partners Inc purchased a new stake in shares of Cellebrite DI during the fourth quarter valued at $85,000. NewEdge Advisors LLC increased its position in Cellebrite DI by 600.7% during the fourth quarter. NewEdge Advisors LLC now owns 3,910 shares of the company's stock valued at $86,000 after acquiring an additional 3,352 shares during the last quarter. Polen Capital Management LLC purchased a new position in Cellebrite DI in the fourth quarter worth about $222,000. Victory Capital Management Inc. purchased a new stake in Cellebrite DI in the fourth quarter worth about $234,000. Finally, Wealth Enhancement Advisory Services LLC bought a new stake in shares of Cellebrite DI during the 1st quarter valued at $269,000. Hedge funds and other institutional investors own 45.88% of the company's stock.

Analysts Set New Price Targets

Several analysts have commented on CLBT shares. JPMorgan Chase & Co. decreased their price target on shares of Cellebrite DI from $29.00 to $25.00 and set an "overweight" rating on the stock in a research note on Monday, May 12th. Needham & Company LLC restated a "buy" rating and set a $24.00 price objective on shares of Cellebrite DI in a research report on Friday, June 6th. Seven equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company currently has an average rating of "Buy" and a consensus price target of $22.43.

Cellebrite DI Stock Performance

CLBT stock traded up $0.12 on Thursday, hitting $15.32. 1,149,670 shares of the company's stock were exchanged, compared to its average volume of 1,474,370. The firm has a 50 day moving average price of $17.37 and a two-hundred day moving average price of $19.55. Cellebrite DI Ltd. has a 12-month low of $11.47 and a 12-month high of $26.30. The stock has a market cap of $3.67 billion, a P/E ratio of -15.95, a price-to-earnings-growth ratio of 3.19 and a beta of 1.28.

Cellebrite DI (NASDAQ:CLBT - Get Free Report) last issued its quarterly earnings results on Wednesday, May 14th. The company reported $0.10 EPS for the quarter, topping the consensus estimate of $0.09 by $0.01. Cellebrite DI had a negative net margin of 46.34% and a positive return on equity of 35.36%. The company had revenue of $107.55 million during the quarter, compared to analyst estimates of $109.36 million. During the same quarter in the previous year, the firm earned $0.08 EPS. The firm's revenue was up 20.0% compared to the same quarter last year. Sell-side analysts expect that Cellebrite DI Ltd. will post 0.3 earnings per share for the current fiscal year.

Cellebrite DI Profile

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.